The Recall Desk

Severity 4 of 5

Severe recalls

The hazard poses a serious risk of illness, injury, or structural failure. Stop using the product immediately and contact the manufacturer for a refund or repair.

What “severe” means here

Severity 4 (Severe) recalls have a real, documented risk of significant injury, hospitalization, or property damage even if no deaths have been reported. The agency classification is FDA Class II with hospitalization reports, USDA Class I, or a structural vehicle defect. These need attention quickly — not five-alarm urgency but not something to put off. Examples include allergen mislabeling on common allergens for products eaten by children, drug potency out of specification by a margin that could cause measurable harm, and vehicle defects affecting braking or steering.

The full rubric is on the methodology page. Severity is computed deterministically from the agency’s own classification plus the source text — no editorial vibes.

23251–23275 of 32176

  • SevereFDA (Drugs)·D-591-2015·2015-04-29

    Attix Pharmaceuticals Recalls Citalopram Hydrobromide Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Citalopram Hydrobromide active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Citalopram Hydrobromide active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-617-2015·2015-04-29

    Attix Pharmaceuticals Recalls Dasatinib API Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Dasatinib active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Dasatinib active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-542-2015·2015-04-29

    Attix Pharmaceuticals Recalls Bethanechol Chloride Due to Penicillin Cross Contamination Risk

    Attix Pharmaceuticals is recalling Bethanechol Chloride active pharmaceutical ingredient due to potential penicillin cross contamination from inadequate facility separation.

    Product
    Bethanechol Chloride active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Food)·F-2024-2015·2015-04-29

    Giant Eagle Recalls Italian Subs for Undeclared Egg Allergen

    Giant Eagle is recalling 4,671 units of GetGo 7-inch Italian subs sold in Maryland, Ohio, Pennsylvania, and West Virginia due to an undeclared egg allergen.

    Product
    GetGo GNG 7 Inch Italian Sub Sell By: (up to and including) 04/02/15 Net Wt: 6.0 Oz. Contains: Soy, Milk, Wheat UPC: 25567 20399 GetGo from Giant Eagle Distributed by Giant Eagle, Inc., Pittsburgh, PA 15238 Sandwich is wrapped in plastic.
    Category
    Food
    Distribution
    0 states
  • SevereFDA (Drugs)·D-913-2015·2015-04-29

    Attix Pharmaceuticals Recalls Tamoxifen Citrate Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Tamoxifen Citrate active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Tamoxifen Citrate active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-853-2015·2015-04-29

    Attix Pharmaceuticals Recalls Pralidoxime Chloride Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Pralidoxime Chloride active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Pralidoxime Chloride active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-916-2015·2015-04-29

    Attix Pharmaceuticals Recalls Tegaserod Maleate Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Tegaserod Maleate active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Tegaserod Maleate active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-721-2015·2015-04-29

    Attix Pharmaceuticals Recalls Hydroxyprogesterone Caproate Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Hydroxyprogesterone Caproate active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Hydroxyprogesterone Caproate active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-587-2015·2015-04-29

    Attix Pharmaceuticals Recalls Cinacalcet HCI Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling all lots of Cinacalcet HCI active pharmaceutical ingredient distributed between January 5, 2012, and February 12, 2015, due to potential penicillin cross-contamination.

    Product
    Cinacalcet HCI active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-952-2015·2015-04-29

    Attix Pharmaceuticals Recalls Venlafaxine HCl Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Venlafaxine HCl active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Venlafaxine HCl active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-947-2015·2015-04-29

    Attix Pharmaceuticals Recalls Ursodiol API Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Ursodiol active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Ursodiol active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-601-2015·2015-04-29

    Attix Pharmaceuticals Recalls Croscarmellose Sodium Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Croscarmellose Sodium pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Croscarmellose Sodium pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-583-2015·2015-04-29

    Attix Pharmaceuticals Recalls Cidofovir Anhydrous Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Cidofovir Anhydrous active pharmaceutical ingredient due to a risk of penicillin cross-contamination during repackaging.

    Product
    Cidofovir Anhydrous active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-746-2015·2015-04-29

    Attix Pharmaceuticals Recalls Labetalol HCl Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Labetalol HCl active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Labetalol HCl active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-772-2015·2015-04-29

    Attix Pharmaceuticals Recalls Mebendazole Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Mebendazole active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Mebendazole active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-895-2015·2015-04-29

    Simvastatin API Recalled for Potential Penicillin Cross Contamination

    Attix Pharmaceuticals is recalling Simvastatin active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Simvastatin active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-795-2015·2015-04-29

    Mevastatin API Recalled for Potential Penicillin Cross-Contamination

    Attix Pharmaceuticals is recalling Mevastatin active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Mevastatin active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-735-2015·2015-04-29

    Attix Pharmaceuticals Recalls Iron Sucrose API Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Iron Sucrose and Ferric Hydroxide Sucrose Complex active pharmaceutical ingredients due to potential penicillin cross-contamination during repackaging.

    Product
    Iron Sucrose or Ferric Hydroxide Sucrose Complex active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-627-2015·2015-04-29

    Attix Pharmaceuticals Recalls Dexrazoxane Due to Penicillin Cross Contamination Risk

    Attix Pharmaceuticals is recalling Dexrazoxane active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Dexrazoxane active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-622-2015·2015-04-29

    Attix Pharmaceuticals Recalls Desoximetasone Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Desoximetasone active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Desoximetasone active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-882-2015·2015-04-29

    Attix Pharmaceuticals Recalls Rivaroxaban API Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Rivaroxaban active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Rivaroxaban active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-937-2015·2015-04-29

    Attix Pharmaceuticals Recalls Tramadol HCl Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Tramadol HCl active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Tramadol HCl active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-807-2015·2015-04-29

    Attix Pharmaceuticals Recalls Montelukast Sodium Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Montelukast Sodium active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Montelukast Sodium active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-577-2015·2015-04-29

    Attix Pharmaceuticals Recalls Chlorobutanol Anhydrous Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Chlorobutanol Anhydrous pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Chlorobutanol Anhydrous pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide